Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew T Bender

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
ACS Sensors|April 7, 2020
Enzymatic Assay for Rapid Measurement of Antiretroviral Drug LevelsAyokunle O Olanrewaju, Benjamin P Sullivan, Jane Y Zhang, et al.
Transport in Porous Media|August 11, 2017
Effective Rheology of Two-Phase Flow in Three-Dimensional Porous Media: Experiment and SimulationSantanu Sinha, Andrew T Bender, Matthew Danczyk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease ModelsPhilipp Haselmayer, Montserrat Camps, Lesley Liu-Bujalski, et al.
Diabetes|January 30, 2007
Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophagesBardia Askari, Jenny E Kanter, Ashley M Sherrid, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trialBenjamin P Sullivan, Cosette A Craig, Andrew T Bender, et al.
Scientific Reports|November 21, 2023
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignanciesSamantha M Goodstal, Jing Lin, Timothy Crandall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 16, 2024
TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of MyositisYin Wu, Aditee Deshpande, Nicholas Geraci, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2020
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of AutoimmunityJaromir Vlach, Andrew T Bender, Melinda Przetak, et al.
Clinical Immunology (Orlando, Fla.)|January 29, 2016
Btk inhibition treats TLR7/IFN driven murine lupusAndrew T Bender, Albertina Pereira, Kai Fu, et al.
Frontiers in Immunology|February 27, 2023
Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseasesThomas Clarke, Pan Du, Satyendra Kumar, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
ACS Sensors|April 7, 2020
Enzymatic Assay for Rapid Measurement of Antiretroviral Drug LevelsAyokunle O Olanrewaju, Benjamin P Sullivan, Jane Y Zhang, et al.
Transport in Porous Media|August 11, 2017
Effective Rheology of Two-Phase Flow in Three-Dimensional Porous Media: Experiment and SimulationSantanu Sinha, Andrew T Bender, Matthew Danczyk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease ModelsPhilipp Haselmayer, Montserrat Camps, Lesley Liu-Bujalski, et al.
Diabetes|January 30, 2007
Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophagesBardia Askari, Jenny E Kanter, Ashley M Sherrid, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trialBenjamin P Sullivan, Cosette A Craig, Andrew T Bender, et al.
Scientific Reports|November 21, 2023
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignanciesSamantha M Goodstal, Jing Lin, Timothy Crandall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 16, 2024
TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of MyositisYin Wu, Aditee Deshpande, Nicholas Geraci, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2020
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of AutoimmunityJaromir Vlach, Andrew T Bender, Melinda Przetak, et al.
Clinical Immunology (Orlando, Fla.)|January 29, 2016
Btk inhibition treats TLR7/IFN driven murine lupusAndrew T Bender, Albertina Pereira, Kai Fu, et al.
Frontiers in Immunology|February 27, 2023
Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseasesThomas Clarke, Pan Du, Satyendra Kumar, et al.
Pageof 5